AVDL - Avadel Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.50
+0.10 (+2.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.40
Open4.42
Bid3.50 x 1000
Ask5.00 x 1100
Day's Range4.42 - 4.56
52 Week Range4.18 - 11.93
Volume66,379
Avg. Volume295,326
Market Cap165.441M
Beta3.06
PE Ratio (TTM)N/A
EPS (TTM)-0.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.83
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    The medical condition 72 percent of Americans don’t know about is stealing sleep and disrupting lives, survey shows

    If left untreated, sleep loss can result in serious medical consequences. A leading cause of sleep loss is a medical condition called nocturia,1 which a staggering 72 percent of Americans have never heard about, according to a new national online survey of 2,040 U.S. adults conducted by The Harris Poll, and endorsed by Caregiver Action Network, National Association for Continence, Prostate Conditions Education Council, and The Simon Foundation for Continence. Nocturia forces individuals to get up more than once per night to urinate.

  • Brandes Investments Expands Stake in Avadel Pharmaceuticals
    GuruFocus.com14 days ago

    Brandes Investments Expands Stake in Avadel Pharmaceuticals

    The firm founded Charles Brandes (Trades, Portfolio), Brandes Investment Partners, on Thursday announced that it expanded its position in Avadel Pharmaceuticals Plc (AVDL) to 13.5% of the company, enlarging its exposure to health care, the second-largest sector represented in its portfolio. Warning! GuruFocus has detected 8 Warning Signs with PFE. The value investing firm has been building its stake in Avadel as the company's stock price has declined.

  • GlobeNewswire22 days ago

    Avadel Pharmaceuticals to Present at the 2018 Wells Fargo Healthcare Conference

    Avadel Pharmaceuticals plc (AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that its Chief Executive Officer, Mike Anderson, will present at the 2018 Wells Fargo Healthcare Conference in Boston on Thursday, September 6, 2018 at 3:40 pm EDT.

  • GlobeNewswire23 days ago

    New Data on NOCTIVA™ Presented at the 2018 International Continence Society Meeting

    Avadel Pharmaceuticals plc (AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, presented new findings today from Phase III clinical trials of AV002 at the International Continence Society (ICS) Meeting in Philadelphia. The data demonstrate nocturia patients treated with AV002 – NOCTIVA™ (desmopressin acetate) Nasal Spray, an emulsified microdose of desmopressin – had a significant reduction in the number of nocturic voids (NOV) among older adults, a longer first uninterrupted sleep period (FUSP) at night, rapid efficacy responses after one dose and a well-tolerated safety profile. The abstracts were entitled, “Extended first uninterrupted sleep period for older adults following treatment with AV002, an emulsified microdose vasopressin analog,” and “Rapid nocturia efficacy of AV002, an emulsified microdose vasopressin analog,” and were presented by Benjamin M. Brucker, M.D., urologist and director of the Center of Female Pelvic Medicine at New York University’s Langone Health and Diane K. Newman, DNP, FAAN, co-director of Penn Center for Continence and Pelvic Health, respectively.

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within Armstrong Flooring, U.S. Global Investors, Aqua Metals, Clearside Biomedical, EP Energy, and Avadel Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Armstrong ...

  • ACCESSWIRElast month

    Avadel Pharmaceuticals PLC Sponsored ADR to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Avadel Pharmaceuticals PLC Sponsored ADR (NASDAQ: AVDL ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at ...

  • Associated Presslast month

    Avadel: 2Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had a loss of 9 cents. The specialty pharmaceutical company posted revenue of $29.2 million in the period. Avadel shares have declined 27 percent ...

  • GlobeNewswirelast month

    Avadel Pharmaceuticals Reports Second Quarter 2018 Financial Results

    DUBLIN, Ireland, Aug. 07, 2018-- Avadel Pharmaceuticals plc, a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced its ...

  • ACCESSWIRE2 months ago

    Breakfast Technical Briefing on Avid Bioservices and Three Other Additional Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on CDMO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • GlobeNewswire2 months ago

    Avadel Pharmaceuticals to Report Second Quarter 2018 Results

    Avadel Pharmaceuticals plc (AVDL), today announced it will report its second quarter 2018 financial results on Tuesday, August 7, 2018, before the market open. For more information, please visit www.avadel.com.

  • Should You Expect Avadel Pharmaceuticals plc (NASDAQ:AVDL) To Continue Delivering An ROE Of 34.61%?
    Simply Wall St.3 months ago

    Should You Expect Avadel Pharmaceuticals plc (NASDAQ:AVDL) To Continue Delivering An ROE Of 34.61%?

    This analysis is intended to introduce important early concepts to people who are starting to invest and looking to gauge the potential return on investment in Avadel Pharmaceuticals plc (NASDAQ:AVDL).Read More...

  • ACCESSWIRE4 months ago

    Free Technical Insights on CASI Pharma and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on CASI sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Associated Press5 months ago

    Avadel: 1Q Earnings Snapshot

    The Dublin-based company said it had a loss of 32 cents per share. The specialty pharmaceutical company posted revenue of $33.3 million in the period. Avadel expects full-year revenue in the range of $105 ...

  • Avadel Pharmaceuticals plc (NASDAQ:AVDL): What’s The Analyst Consensus Outlook?
    Simply Wall St.5 months ago

    Avadel Pharmaceuticals plc (NASDAQ:AVDL): What’s The Analyst Consensus Outlook?

    In December 2017, Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced its latest earnings update, which confirmed that the business finally turned profitable after delivering negative earnings on average over the last coupleRead More...

  • Benzinga6 months ago

    Jazz Pharma Upgraded On Bullish Pipeline Forecast, Earnings Growth Visibility, M&A Potential

    Morgan Stanley named three reasons for its positive opinion on Irish pharma company Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) in a Monday report.  The Analyst Analyst David Risinger upgraded shares of Jazz ...